Précisez une action ou une cryptomonnaie dans la barre de recherche pour obtenir un récapitulatif
Sichuan Kelun-Biotech
6990Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs to address unmet medical needs in the People's Republic of China and internationally. The company is developing various drugs to treat breast, non-small cell lung, and gastrointestinal cancer, as well as non-oncology diseases. Its product pipeline includes oncology drug candidates, such as SKB264 (sacituzumab tirumotecan), A166 (trastuzumab botidotin), SKB315, A167 (tagitanlimab), A140, and A400; and non-oncology drug candidates primarily to treat immune-mediated diseases, consisting of rheumatoid arthritis and alopecia areata comprising A223, A277, SKB378, and SKB336. The company has license and collaboration arrangements with Merck Sharp & Dohme LLC; Harbour BioMed Therapeutics Limited; and Ellipses Pharma Limited. The company was incorporated in 2016 and is headquartered in Chengdu, the People's Republic of China. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. operates as a subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd. Address: No. 666 Xinhua Avenue, Chengdu, China
Analytics
Objectif de Cours de WallStreet
1 677.46 HKDRatio C/B
–Rendement du dividende
–Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Chiffres clés 6990
Analyse des dividendes 6990
Croissance des dividendes sur 5 ans
–Croissance continue
–Ratio de distribution Moyenne sur 5 ans
–Historique des dividendes 6990
Valorisation des titres 6990
financières 6990
Résultats | 2019 | Dynamique |